Clinical Trials | October 30, 2023
SN Bioscience announces Phase 1 study results of SN-38 nanoparticle anti-cancer drug
Impressive safety and efficacy for solid cancer patients followed by global clinical study plan
Impressive safety and efficacy for solid cancer patients followed by global clinical study plan
The company expects that this development could improve the strength of its application to the FDA for new drug approval
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
Approval of oral, once-daily VELSIPITY based on favorable safety and efficacy data from the ELEVATE UC Phase 3 trials
Tagrisso is projected to be a pivotal contributor to AstraZeneca’s portfolio
This integrated care offering is a step forward in our vision of providing an effective continuum of care for patients
Glenmark will receive from Cassiopea, a subsidiary of Cosmo, the exclusive right to commercialize Winlevi in 15 EU countries
The complexity of operating on a one-year-old are many with the organs being tiny, fragile
Alleviating staff shortages by empowering surgeons with greater personalization and control
Parecoxib Sodium is the first parenteral selective COX-2 inhibitor available for clinical use in pain management
Subscribe To Our Newsletter & Stay Updated
